Delicious
Digg
Facebook
LinkedIn
Twitter
WALTHAM, Mass., Nov. 2, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Company management will present at two investor conferences in the coming weeks.
The webcast of each presentation can be accessed live through the "Investor Information" section of the Company's website, www.immunogen.com; a replay of each presentation will be available at the same location for one week. About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development and a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.
9:00 am MST/11:00 am EST on November 11, 2011 in Phoenix, AZ
Presenter: Daniel Junius, President and CEO
11:30 am EST on November 15, 2011 in New York, NY
Presenter: Daniel Junius, President and CEOCONTACT: For Investors:
Carol Hausner
Executive Director,
Investor Relations and Corporate Communications
ImmunoGen, Inc.
(781) 895-0600
info@immunogen.com
For Media:
Barbara Yates
The Yates Network
(781) 258-6153
Mixx
Yahoo! Buzz